First Nebraska Trust Co Purchases New Stake in Colgate-Palmolive Company $CL

Posted by George Bondi on Nov 4th, 2026

First Nebraska Trust Co acquired a new position in Colgate-Palmolive Company (NYSE:CL – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 61,567 shares of the company’s stock, valued at approximately $5,252,000.

A number of other hedge funds also recently bought and sold shares of the stock. Virginia Estate & Retirement Planning Advisors Inc. grew its stake in Colgate-Palmolive by 1,409.1% during the 3rd quarter. Virginia Estate & Retirement Planning Advisors Inc. now owns 332 shares of the company’s stock worth $28,000 after buying an additional 310 shares during the last quarter. Parvin Asset Management LLC purchased a new stake in Colgate-Palmolive in the second quarter valued at about $32,000. Park Place Capital Corp raised its stake in Colgate-Palmolive by 55.5% in the second quarter. Park Place Capital Corp now owns 356 shares of the company’s stock valued at $33,000 after buying an additional 127 shares during the last quarter. Gould Capital LLC raised its stake in Colgate-Palmolive by 38.7% in the first quarter. Gould Capital LLC now owns 412 shares of the company’s stock valued at $35,000 after buying an additional 115 shares during the last quarter. Finally, Montgomery Financial Services LLC acquired a new stake in Colgate-Palmolive in the second quarter worth about $36,000. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Stock Down 2.1%

Shares of CL stock opened at $95.36 on Wednesday. The stock has a 50 day moving average of $89.73 and a 200 day moving average of $89.77. The company has a current ratio of 0.96, a quick ratio of 0.30 and a debt-to-equity ratio of 11.23. The stock has a market cap of $75.80 billion, a P/E ratio of 25.11, a P/E/G ratio of 4.55 and a beta of 0.31. Colgate-Palmolive Company has a twelve month low of $75.00 and a twelve month high of $99.33.

Colgate-Palmolive (NYSE:CL – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. The company had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.34 billion. During the same quarter last year, the business earned $0.91 earnings per share. The firm’s revenue was up 4.6% on a year-over-year basis. As a group, sell-side analysts expect that Colgate-Palmolive Company will post 3.91 EPS for the current year.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Tuesday, October 20th will be given a dividend of $0.53 per share. The ex-dividend date is Tuesday, October 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.2%. Colgate-Palmolive’s payout ratio is presently 83.14%.

Insider Buying and Selling

In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 10,000 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $92.05, for a total transaction of $920,500.00. Following the completion of the transaction, the chief operating officer owned 64,901 shares of the company’s stock, valued at $5,974,137.05. This trade represents a 13.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John T. Cahill sold 4,170 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total value of $389,352.90. Following the completion of the sale, the director owned 28,373 shares in the company, valued at $2,649,187.01. This represents a 12.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.43% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of Colgate-Palmolive from $104.00 to $102.00 and set an “overweight” rating on the stock in a report on Monday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Colgate-Palmolive in a research note on Thursday, August 13th. Raymond James Financial lifted their target price on shares of Colgate-Palmolive from $100.00 to $102.00 and gave the stock an “outperform” rating in a research note on Monday, August 3rd. Weiss Ratings downgraded shares of Colgate-Palmolive from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 2nd. Finally, Wells Fargo & Company boosted their target price on shares of Colgate-Palmolive from $90.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Monday. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.22.

Get Our Latest Stock Report on Colgate-Palmolive

Key Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

Positive Sentiment: Colgate-Palmolive beat third-quarter estimates, with sales up 4.6% year over year, and raised its EPS outlook while narrowing its 2026 sales outlook. Management cited resilient global demand and premium innovation, although costs remain a pressure. Q3 deep dive
Positive Sentiment: Several analysts raised their targets after the results. Morgan Stanley lifted its target to $111 and kept an overweight rating; BNP Paribas Exane raised its target to $108 and reaffirmed outperform; RBC raised its target to $105 and maintained outperform. Analyst forecasts after Q3 earnings
Neutral Sentiment: JPMorgan trimmed its target to $102 but retained an overweight rating. Barclays and Wells Fargo raised their targets to $95 while keeping equal-weight ratings, signaling limited upside at those firms’ estimates.
Negative Sentiment: A valuation comparison noted that Colgate-Palmolive trades at a higher forward price-to-earnings multiple than Lululemon, raising questions about whether CL’s premium valuation is justified. Valuation comparison

About Colgate-Palmolive

(Free Report)

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.